clinical_trials
Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention
Confidence86·multiple reportsImportance88NP-EVT-20261110-64ABFD0
(MedPage Today) -- The FDA approved asundexian (Sunharbo) as the first factor XIa (FXIa) inhibitor for secondary stroke prevention, the agency announced on Monday. Asundexian, an oral, direct, small-molecule inhibitor of FXIa, is indicated for...
Read the original at the primary source
Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention
11/10/2026, 7:18:57 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —